ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Monday, November 13, 2023

9:00AM-11:00AM: Abstract Number: 0860

Vagus Nerve Stimulation Enhances Bone Morphology in a Rodent Model of Central Nervous System Inflammation

(0859–0885) Osteoarthritis & Joint Biology – Basic Science Poster

9:00AM-11:00AM: Abstract Number: 0974

Validation of Boolean 2.0 Criteria for Assessing Remission and Predicting Quality of Life in Korean Patients with Rheumatoid Arthritis Undergoing Targeted Therapy

(0965–0992) Epidemiology & Public Health Poster II

9:00AM-11:00AM: Abstract Number: 1051

Validation of Handheld Ultrasound Devices for Point of Care Use in Rheumatology: Interim Analysis

(1033–1051) Imaging of Rheumatic Diseases Poster I

9:00AM-11:00AM: Abstract Number: 1545

Validation of the 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria in Patients with ANCA-associated Vasculitis

(1534–1553) Vasculitis – ANCA-Associated Poster II: Epidemiology, Outcomes, & Classification

9:00AM-11:00AM: Abstract Number: 1228

Validation of the PEDiatric Behçet’s Disease Classification Criteria (PEDBD): An International Consensus-based Approach

(1221–1255) Pediatric Rheumatology – Clinical Poster II: Connective Tissue Disease

9:00AM-11:00AM: Abstract Number: 1305

Variations in Macrophage Cholesterol Loading over Time Are Linked to Dynamic Changes in Coronary Atherosclerotic Plaque in Rheumatoid Arthritis

(1264–1307) RA – Diagnosis, Manifestations, and Outcomes Poster II

9:00AM-11:00AM: Abstract Number: 1061

Vasculitis as an Immune-Related Adverse Event: Unraveling the Complexities at the Intersection of Immunology and Vascular Pathology

(1052–1081) Immunological Complications of Medical Therapy Poster

9:00AM-11:00AM: Abstract Number: 1443

Vasculitis Associations Among Patients with Systemic Lupus Erythematous

(1442–1487) SLE – Diagnosis, Manifestations, & Outcomes Poster II

9:00AM-11:00AM: Abstract Number: 1259

Voices Unheard: Unmasking the Hidden Challenges of Youth with Rheumatic Diseases

(1256–1263) Psychology/Social Science – Interprofessional Poster

9:00AM-11:00AM: Abstract Number: 1279

What Is the Nature of Functional Problems in People with Rheumatoid Arthritis and Severe Disability; An Analysis Using the International Classification of Functioning, Disability and Health as a Reference

(1264–1307) RA – Diagnosis, Manifestations, and Outcomes Poster II

9:00AM-11:00AM: Abstract Number: 1385

Where Are We with Implementing Axial Spondyloarthritis Treatment Recommendations and Disease Activity Monitoring in Clinical Practice – Results of an Online Survey Amongst Rheumatology Care Providers

(1383–1411) Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster II: Imaging & AS

9:00AM-11:00AM: Abstract Number: 0996

Will Patients Engage with Digital Technologies as Part of Routine Healthcare?

(0993–1012) Health Services Research Poster II

9:00AM-11:00AM: Abstract Number: 1304

Window of Opportunity to Achieve Better Functional Outcomes in Patients with RA: Effectiveness of an Early Treatment Strategy

(1264–1307) RA – Diagnosis, Manifestations, and Outcomes Poster II

9:00AM-11:00AM: Abstract Number: 1190

Worsening of Pain as Perceived by Patients Is Not Reflected by an Annual Standardized Questionnaire

(1183–1199) Osteoarthritis – Clinical Poster II

9:00AM-11:00AM: Abstract Number: 1499

Year-5 Follow-up of Belimumab Safety (mortality and Malignancies) in Patients with Systemic Lupus Erythematosus (SLE) Who Completed a Phase 4, 52-week, Randomized, Double-blind Placebo-controlled Safety Study

(1488–1512) SLE – Treatment Poster II

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].